March 14, 2011
In early-stage study results reported recently to investors, Gilead Sciences Inc. said its four-drug combination eliminated hepatitis C virus in patients. The trial examined the use of Gilead GS-9256 and GS-9190 with the standard drugs ribavirin and peginterferon. The researchers plan to present their findings at the annual meeting of the European Association for the Study of the Liver, which begins March 30 in Berlin.
No comments have been made.
|This Week in HIV Research: Antibody Being Tested for HIV Prevention, and Differing Results on HCV Treatment in Coinfection|
|Which Hepatitis C Treatment to Start in 2016|
|What's the Most Overlooked Issue in HIV Care Today?|
|Using Saliva as Lube Can Cause Rectal Gonorrhea|
|This Week in HIV Research: When New Meets Old|